Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03412643 |
| Title | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12) |
| Acronym | FB-12 |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | NSABP Foundation Inc |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |